Abstracts tagged "Biologic agents"

Abstract Number: 432 • 2013 ACR/ARHP Annual Meeting
Use Of Rituximab As Second Line Biologic Agent Compared With Adalimumab, Etanercept and Infliximab In Patients With Rheumatoid Arthritis. a Report From The Rhumadata® Clinical Database and Registry
Louis Bessette¹, Denis Choquette², Diane Sauvageau³, Boulos Haraoui⁴, Jean Pierre Pelletier², Jean-Pierre Raynauld³, Edith Villeneuve³ and Louis Coupal², ¹Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, Canada, ²Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ³Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ⁴Rhumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada
Background/Purpose: The order of use of biologic agents after failing a TNF inhibitor is still a question for debate. Phase III trial data in TNF-IR…
Abstract Number: L10 • 2012 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis Patients with Stable Low Disease Activity On Methotrexate Plus Etanercept, Continuation of Etanercept 50 Mg Weekly or 25 Mg Weekly Are Both Clinically Superior to Discontinuation: Results From a Randomized, 3-Armed, Double-Blind Clinical Trial
R.F. van Vollenhoven¹, Mikkel Østergaard², Marjatta Leirisalo-Repo³, Till Uhlig⁴, Marita Jansson⁵, Åsa Klackenberg⁵, Katherine Hutchinson⁶ and Karin Franck-Larsson⁵, ¹Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden, ²Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ³Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland, ⁴Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Speciality Care Nordic Medical Affairs, Pfizer Nordic, Sollentuna, Sweden, ⁶Quanticate, Hitchin, United Kingdom
Background/Purpose: The efficacy of etanercept (ETN) in combination with methotrexate (MTX) in the treatment of rheumatoid arthritis (RA) is well established, and long-term trials1 and…
Abstract Number: L4 • 2012 ACR/ARHP Annual Meeting
Continued Improvement of Signs and Symptoms in Patients with Active Psoriatic Arthritis: Week 52 Results of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study
Arthur Kavanaugh¹, Iain B. McInnes², Alice B. Gottlieb³, Lluis Puig⁴, Proton Rahman⁵, Christopher T. Ritchlin⁶, Shu Li⁷, Yuhua Wang⁷, Mittie K. Doyle⁸ and Alan M. Mendelsohn⁹, ¹UCSD School of Medicine, La Jolla, CA, ²University of Glasgow, Glasgow, Scotland, ³Tufts Medical Center, Boston, MA, ⁴Universitat Autònoma de Barcelona, Barcelona, Spain, ⁵Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁶Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁷Janssen Research & Development, LLC., Spring House, PA, ⁸Janssen Research & Development, LLC, Spring House, PA, ⁹Immunology, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: PSUMMIT I ,through wk24, demonstrated efficacy and safety of ustekinumab (UST) in reducing signs and symptoms of active psoriatic arthritis (PsA) in a large,…
Abstract Number: L7 • 2012 ACR/ARHP Annual Meeting
Tapering TNF-Blockers in Established Rheumatoid Arthritis Patients in DAS28 Remission: Results of a DAS28-Driven Step-Down Strategy Randomized Controlled Trial
Bruno Fautrel¹, Thao Pham², Florence Tubach³, Toni Alfaiate⁴, Jacques Morel⁵, Emmanuelle Dernis⁶, Xavier J. Puechal⁷, Philippe Gaudin⁸ and Xavier Mariette⁹, ¹Rheumatology, UPMC - Paris 6 University, Paris, France, ²Rheumatology Department, Sainte Marguerite Hospital, Marseille, France, ³Département d'Epidémiologie Biostatistique et Recherche Clinique, APHP, Hôpital Bichat, Paris, France, ⁴Biostatistics, Bichat Hospital, AP-HP, Paris, France, ⁵Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France, ⁶Centre Hospitalier, Le Mans, France, ⁷Le Mans Hospital, Le Mans, France, ⁸Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ⁹Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France
Background/Purpose: Step-down therapeutic strategies are often considered in established rheumatoid arthritis (RA) once remission is achieved but are associated with a potential risk of relapse…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].